PROCEPT BioRobotics (PRCT) Common Equity (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Common Equity data on file, last reported at $347.7 million in Q1 2026.

• On a quarterly basis, Common Equity fell 10.66% year-over-year to $347.7 million in Q1 2026; TTM through Mar 2026 was $347.7 million, a 10.66% decrease from a year earlier, with the FY2025 full-year figure at $365.9 million, down 9.04% from the prior year.
• Common Equity for Q1 2026 stood at $347.7 million, down from $365.9 million in the prior quarter.
• Over the last five years, Common Equity for PRCT reached as high as $402.2 million in Q4 2024 and fell as low as $155.9 million in Q2 2023.
• Historically, Common Equity has averaged $285.1 million across 5 years, with a median of $264.0 million in 2024.
• Across the five-year window, Common Equity soared 230.38% in 2022 and tumbled 34.82% in 2023, its largest moves.
• Year by year, Common Equity stood at $197.1 million in 2022, then surged by 42.46% to $280.8 million in 2023, then soared by 43.27% to $402.2 million in 2024, then decreased by 9.04% to $365.9 million in 2025, then fell by 4.98% to $347.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $347.7 million in Q1 2026, $365.9 million in Q4 2025, and $380.3 million in Q3 2025.